Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.34 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.32 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | MAOA | P21397 | 2/20 | 0.31 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4142908 | 0.82 | NPY5R (0.47) | ALKBH5FTONPY5RHTR1ABDKRB1 | |
| SCHEMBL4155517 | 0.80 | ALKBH5 (0.34) | ALKBH5FTONPY5RHTR1ABDKRB1 | |
| SCHEMBL4148884 | 0.79 | CYP3A4 (0.41) | CYP3A4BDKRB1KDM1AMAOAMAOB | |
| SCHEMBL4149466 | 0.78 | BDKRB1 (0.37) | ALKBH5FTOMAPTNPY5RHTR1A | |
| SCHEMBL4134116 | 0.78 | BDKRB1 (0.43) | ALKBH5HTR1ABDKRB1 | |
| SCHEMBL4808441 | 0.77 | ATM (0.55) | KDM4EALDH1A1 | |
| SCHEMBL4145157 | 0.77 | ALDH1A1 (0.41) | ALKBH5FTOHTR1ABDKRB1KDM4E | |
| SCHEMBL4145560 | 0.77 | NPY5R (0.35) | NPY5RHTR1ABDKRB1KDM4E | |
| SCHEMBL4150330 | 0.76 | HRH3 (0.42) | CYP3A4BDKRB1KDM1AMAOAMAOB | |
| SCHEMBL5951049 | 0.76 | BDKRB1 (0.44) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-7425631-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-09-16 | — | — | US | disclosed |
| EP-1631542-A1 | BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF | Amgen, Inc. (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20050124654-A1 | Compounds and methods of use | AMGEN INC. | 2005-06-09 | — | — | US | disclosed |
| WO-2004092116-A1 | BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF | AMGEN, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124654-A1 | Compounds and methods of use | LTC4S, PTGES, LTB4R2 | DPP7 485/4885ALKBH5 1697/4885FTO 2580/4885 |
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | LTC4S, PTGES, LTB4R2 | DPP7 485/4885ALKBH5 1697/4885FTO 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.